Globenewswire

19 July 2021

Recruitment for Phase 2 Trial of Lyme Disease Vaccine completed by Pfizer

Valneva SE a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate’s pediatric program.
16 July 2021

HIV Cure Program Releases Initial Clinical Trial Data

American Gene Technologies announced that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGTs HIV cure program without modification, after safety analysis of the participants data revealed no adverse effects from the treatment. AGTs Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient's immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused.